Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias - Shah, Nirali N.; Merchant, Melinda S.; Cole, Diane E.; Jayaprakash, Nalini; Bernstein, Donna; Delbrook, Cindy; Richards, Kelly; Widemann, Brigitte C.; Wayne, Alan S. (Pediatric blood & cancer, 2016)
Keywords: acute lymphoblastic leukemia; Adolescent; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - pharmacokinetics; Chemotherapy; Child; Child, Preschool; Female; Hematology; Humans; Leukemia; Liposomes; Male; Marqibo; Maximum Tolerated Dose; Neoplasms - drug therapy; Oncology; pediatric; Pediatrics; phase I; Registries; Vincristine - administration & dosage; Vincristine - adverse effects; Vincristine - pharmacokinetics; Young Adult; Marqibo; phase I; acute lymphoblastic leukemia; pediatric